Faruqi & Faruqi Investigates Regencell Securities Fraud Claims
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Regencell Bioscience Holdings Limited, urging investors who purchased securities between October 28, 2024, and October 31, 2025, to contact them before the June 23, 2026, deadline to seek lead plaintiff status.
- Market Manipulation Risks: The complaint alleges that Regencell and its executives violated federal securities laws by failing to disclose the company's vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny, which could harm the company's reputation.
- Stock Price Plunge Impact: Following the October 31, 2025, disclosure of a subpoena from the U.S. Department of Justice, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share, resulting in substantial losses for investors.
- Investor Rights Protection: Faruq & Faruqi encourages investors who purchased Regencell securities during the Class Period to contact the firm to discuss their legal rights and participate in the class action lawsuit to seek compensation, ensuring that investors are adequately protected in the legal process.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGC
About RGC
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Investigates Regencell Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Regencell Bioscience Holdings Limited, urging investors who purchased securities between October 28, 2024, and October 31, 2025, to contact them before the June 23, 2026, deadline to seek lead plaintiff status.
- Market Manipulation Risks: The complaint alleges that Regencell and its executives violated federal securities laws by failing to disclose the company's vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny, which could harm the company's reputation.
- Stock Price Plunge Impact: Following the October 31, 2025, disclosure of a subpoena from the U.S. Department of Justice, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share, resulting in substantial losses for investors.
- Investor Rights Protection: Faruq & Faruqi encourages investors who purchased Regencell securities during the Class Period to contact the firm to discuss their legal rights and participate in the class action lawsuit to seek compensation, ensuring that investors are adequately protected in the legal process.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, consistently ranking in the top four since 2013, demonstrating its expertise and success in this field.
- Case Details Unveiled: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, highlighting potential legal and reputational harm to investors.
See More
Regencell Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny and legal repercussions.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of safeguarding their rights in the legal proceedings.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, demonstrating its expertise and influence in protecting investor interests.
See More
Regencell Faces Class Action Lawsuit Amidst Stock Volatility
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, seeking damages for violations of federal securities laws, highlighting significant investor concerns regarding corporate governance and transparency.
- Stock Price Volatility: Regencell's share price soared to $78.00 on June 17, 2025, marking a staggering 48,650% increase from the start of the class period, but subsequently plummeted to just above $20.00, reflecting a lack of confidence in the company's fundamentals and exposing investors to substantial financial risks.
- Insufficient R&D Investment: Despite claims of developing traditional Chinese medicine for ADHD and autism, Regencell's R&D expenditures were only $0.95 million and $1.07 million for 2025 and 2024, respectively, significantly lower than the average costs for new drug development, raising doubts about the sustainability of its business model.
- Regulatory Investigation Risk: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice regarding its stock trading, indicating potential legal costs and fines, which further exacerbates market uncertainty regarding its future prospects.
See More
Regencell's $14 Billion Valuation Plummets 18.56% Amid DOJ Investigation
- Valuation Collapse: Regencell's market valuation plummeted 18.56% following a subpoena from the U.S. Department of Justice, with shares dropping $3.09 to close at $13.56, indicating severe market concerns over its operational transparency.
- Zero Revenue Operations: Despite a staggering $14 billion market cap, Regencell operates with only twelve employees and spends approximately $1 million annually on R&D, highlighting a significant disconnect between its valuation and actual business fundamentals, which may trigger a crisis of investor confidence.
- Market Manipulation Investigation: The company is accused of failing to disclose risks of market manipulation while attributing stock volatility to short-selling and social media commentary, leading to investor losses under misleading circumstances.
- Legal Action Initiated: A class action lawsuit has been filed on behalf of shareholders who purchased stock between October 28, 2024, and October 31, 2025, seeking compensation for losses, reflecting strong investor dissatisfaction with the company's inadequate disclosures.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: Several publicly traded companies, including Regencell Bioscience Holdings and SES AI Corporation, are facing class action lawsuits for allegedly making false or misleading statements, with investors required to file lead plaintiff motions by specified deadlines to protect their rights.
- Regencell Bioscience Allegations: From October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny, thereby impacting its reputation and financial stability.
- SES AI Lawsuit Details: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, failing to disclose logistics constraints that affected Q4 2025 revenues, raising doubts about its growth prospects for 2026 and undermining investor confidence.
- FS KKR and Graphic Packaging Allegations: FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, while Graphic Packaging faces significant negative impacts on its financial results due to inventory management issues and reduced demand, leading to misleading positive statements about its business operations.
See More
Faruqi & Faruqi Investigates Regencell Securities Fraud Claims
- Legal Investigation Launched: Faruq & Faruqi LLP is investigating potential securities fraud claims against Regencell Bioscience Holdings Limited, urging investors who purchased securities between October 28, 2024, and October 31, 2025, to contact them before the June 23, 2026, deadline to seek lead plaintiff status.
- Market Manipulation Risks: The complaint alleges that Regencell and its executives violated federal securities laws by failing to disclose the company's vulnerability to market manipulation, exposing investors to significant financial risks and potential regulatory scrutiny, which could harm the company's reputation.
- Stock Price Plunge Impact: Following the October 31, 2025, disclosure of a subpoena from the U.S. Department of Justice, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share, resulting in substantial losses for investors.
- Investor Rights Protection: Faruq & Faruqi encourages investors who purchased Regencell securities during the Class Period to contact the firm to discuss their legal rights and participate in the class action lawsuit to seek compensation, ensuring that investors are adequately protected in the legal process.
See More
Regencell Securities Class Action Notice
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
- No Upfront Fees: Investors joining the class action will incur no out-of-pocket fees or costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and was ranked No. 1 by ISS Securities Class Action Services in 2017, consistently ranking in the top four since 2013, demonstrating its expertise and success in this field.
- Case Details Unveiled: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation risks and significant financial losses, highlighting potential legal and reputational harm to investors.
See More
Regencell Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, indicating significant legal risks for the company.
- Allegations of Misrepresentation: The lawsuit alleges that Regencell made false and misleading statements regarding its business operations and compliance policies, exposing investors to substantial financial risks and potential regulatory scrutiny and legal repercussions.
- Investor Rights Protection: Investors must apply by June 23, 2026, to be appointed as lead plaintiffs in the lawsuit, highlighting the importance of safeguarding their rights in the legal proceedings.
- Law Firm Background: Bragar Eagel & Squire is a nationally recognized law firm specializing in shareholder rights, securities, and commercial litigation, demonstrating its expertise and influence in protecting investor interests.
See More
Regencell Faces Class Action Lawsuit Amidst Stock Volatility
- Class Action Filed: Pomerantz LLP has initiated a class action lawsuit against Regencell in the U.S. District Court for Maryland on behalf of investors who purchased securities between October 28, 2024, and October 31, 2025, seeking damages for violations of federal securities laws, highlighting significant investor concerns regarding corporate governance and transparency.
- Stock Price Volatility: Regencell's share price soared to $78.00 on June 17, 2025, marking a staggering 48,650% increase from the start of the class period, but subsequently plummeted to just above $20.00, reflecting a lack of confidence in the company's fundamentals and exposing investors to substantial financial risks.
- Insufficient R&D Investment: Despite claims of developing traditional Chinese medicine for ADHD and autism, Regencell's R&D expenditures were only $0.95 million and $1.07 million for 2025 and 2024, respectively, significantly lower than the average costs for new drug development, raising doubts about the sustainability of its business model.
- Regulatory Investigation Risk: On October 31, 2025, Regencell disclosed receiving a subpoena from the U.S. Department of Justice regarding its stock trading, indicating potential legal costs and fines, which further exacerbates market uncertainty regarding its future prospects.
See More
Regencell's $14 Billion Valuation Plummets 18.56% Amid DOJ Investigation
- Valuation Collapse: Regencell's market valuation plummeted 18.56% following a subpoena from the U.S. Department of Justice, with shares dropping $3.09 to close at $13.56, indicating severe market concerns over its operational transparency.
- Zero Revenue Operations: Despite a staggering $14 billion market cap, Regencell operates with only twelve employees and spends approximately $1 million annually on R&D, highlighting a significant disconnect between its valuation and actual business fundamentals, which may trigger a crisis of investor confidence.
- Market Manipulation Investigation: The company is accused of failing to disclose risks of market manipulation while attributing stock volatility to short-selling and social media commentary, leading to investor losses under misleading circumstances.
- Legal Action Initiated: A class action lawsuit has been filed on behalf of shareholders who purchased stock between October 28, 2024, and October 31, 2025, seeking compensation for losses, reflecting strong investor dissatisfaction with the company's inadequate disclosures.
See More
Multiple Companies Face Class Action Lawsuits
- Class Action Overview: Several publicly traded companies, including Regencell Bioscience Holdings and SES AI Corporation, are facing class action lawsuits for allegedly making false or misleading statements, with investors required to file lead plaintiff motions by specified deadlines to protect their rights.
- Regencell Bioscience Allegations: From October 2024 to October 2025, Regencell is accused of failing to disclose its vulnerability to market manipulation, exposing investors to significant financial risks and increasing the likelihood of regulatory scrutiny, thereby impacting its reputation and financial stability.
- SES AI Lawsuit Details: SES AI is alleged to have overstated its business prospects from January 2025 to March 2026, failing to disclose logistics constraints that affected Q4 2025 revenues, raising doubts about its growth prospects for 2026 and undermining investor confidence.
- FS KKR and Graphic Packaging Allegations: FS KKR is accused of overstating the effectiveness of its portfolio restructuring efforts, while Graphic Packaging faces significant negative impacts on its financial results due to inventory management issues and reduced demand, leading to misleading positive statements about its business operations.
See More
